Associations of CYP2A6 genotype with smoking behaviors in southern China

Addiction

Volumn 106, Issue 5, 2011, Pages 985-994

  Liu, Tao ^a   David, Sean P ^b,c,d   Tyndale, Rachel F ^e   Wang, Hui ^a   Zhou, Qian ^e   Ding, Peng ^a   He, Yan Hui ^a   Yu, Xue Qing ^f   Chen, Wei ^f   Crump, Casey ^b   Wen, Xiao Zhong ^g   Chen, Wei Qing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b STANFORD UNIVERSITY   (United States)

^c SRI INTERNATIONAL   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^g BROWN UNIVERSITY   (United States)

Author keywords

Chinese smokers; CYP2A6; Genetic polymorphisms; Nicotine dependence; Smoking cessation; Smoking duration; Smoking initiation; Smoking quantity

Indexed keywords

COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; NICOTINE; NICOTINIC AGENT; UNSPECIFIC MONOOXYGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; CHINA; EPIDEMIOLOGY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; ONSET AGE; PHENOTYPE; POLYMERASE CHAIN REACTION; SMOKING; SMOKING CESSATION; SOCIOECONOMICS; STATISTICS; TIME;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; EPIDEMIOLOGIC METHODS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SMOKING; SMOKING CESSATION; SOCIOECONOMIC FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 79953768162     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03353.x     Document Type: Article

References (69)

1. Liu B. Q., Peto R., Chen Z. M., Boreham J., Wu Y. P., Li J. Y. etal. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 1998; 317: 1411-22.
2. Yang G., Fan L., Tan J., Qi G., Zhang Y., Samet J. M. etal. Smoking in China: findings of the 1996 National Prevalence Survey. JAMA 1999; 282: 1247-53.
3. Niu S. R., Yang G. H., Chen Z. M., Wang J. L., Wang G. H., He X. Z. etal. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. BMJ 1998; 317: 1423-4.
4. World Health Organization (WHO). Towards a Tobacco-Free China. Geneva, Switzerland: WHO; 2007. Available at: (accessed 15 August 2007).
5. Murray C. J., Lopez A. D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
6. Yang G., Ma J., Chen A., Zhang Y., Samet J. M., Taylor C. E. etal. Smoking cessation in China: findings from the 1996 national prevalence survey. Tob Control 2001; 10: 170-4.
7. Li M. D., Cheng R., Ma J. Z., Swan G. E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003; 98: 23-31.
8. Li M. D., Ma J. Z., Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet 2004; 66: 382-92.
9. Han S., Gelernter J., Luo X., Yang B. Z. Meta-analysis of 15 genome-wide linkage scans of smoking behavior. Biol Psychiatry 2010; 67: 12-9.
10. Wang J., Li M. D. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 2010; 35: 702-19.
11. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010; 42: 441-7.
12. Hukkanen J., Jacob P. III, Benowitz N. L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79-115.
13. Benowitz N. L., Perez-Stable E. J., Herrera B., Jacob P. III. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 2002; 94: 108-15.
14. Sellers E. M., Kaplan H. L., Tyndale R. F. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68: 35-43.
15. Nakajima M., Yokoi T. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab Pharmacokinet 2005; 20: 227-35.
16. Mwenifumbo J. C., Tyndale R. F. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007; 8: 1385-402.
17. Oscarson M., McLellan R. A., Gullsten H., Yue Q. Y., Lang M. A., Bernal M. L. etal. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448: 105-10.
18. Nunoya K. I., Yokoi T., Kimura K., Kainuma T., Satoh K., Kinoshita M. etal. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3, 5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 1999; 289: 437-42.
19. Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J. T., Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74: 69-76.
20. Mwenifumbo J. C., Myers M. G., Wall T. L., Lin S. K., Sellers E. M., Tyndale R. F. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 2005; 15: 189-92.
21. Mwenifumbo J. C., Lessov-Schlaggar C. N., Zhou Q., Krasnow R. E., Swan G. E., Benowitz N. L. etal. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 2008; 83: 115-21.
22. Schoedel K. A., Hoffmann E. B., Rao Y., Sellers E. M., Tyndale R. F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 2004; 14: 615-26.
23. Audrain-McGovern J., Al Koudsi N., Rodriguez D., Wileyto E. P., Shields P. G., Tyndale R. F. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 2007; 119: e264-74.
24. Minematsu N., Nakamura H., Furuuchi M., Nakajima T., Takahashi S., Tateno H. etal. Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur Respir J 2006; 27: 289-92.
25. Malaiyandi V., Lerman C., Benowitz N. L., Jepson C., Patterson F., Tyndale R. F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006; 11: 400-9.
26. Oscarson M., McLellan R. A., Gullsten H., Agundez J. A., Benitez J., Rautio A. etal. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460: 321-7.
27. Nakajima M., Fukami T., Yamanaka H., Higashi E., Sakai H., Yoshida R. etal. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 2006; 80: 282-97.
28. Peamkrasatam S., Sriwatanakul K., Kiyotani K., Fujieda M., Yamazaki H., Kamataki T. etal. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet 2006; 21: 475-84.
29. Gyamfi M. A., Fujieda M., Kiyotani K., Yamazaki H., Kamataki T. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 2005; 60: 855-7.
30. Nurfadhlina M., Foong K., Teh L. K., Tan S. C., Mohd Zaki S., Ismail R. CYP2A6 polymorphisms in Malays, Chinese and Indians. Xenobiotica 2006; 36: 684-92.
31. Huang S., Cook D. G., Hinks L. J., Chen X. H., Ye S., Gilg J. A. etal. CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. Pharmacogenet Genomics 2005; 15: 839-50.
32. O'Loughlin J., Paradis G., Kim W., DiFranza J., Meshefedjian G., McMillan-Davey E. etal. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 2004; 13: 422-8.
33. Gu D. F., Hinks L. J., Morton N. E., Day I. N. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64: 383-90.
34. Rao Y., Hoffmann E., Zia M., Bodin L., Zeman M., Sellers E. M. etal. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58: 747-55.
35. Minematsu N., Nakamura H., Iwata M., Tateno H., Nakajima T., Takahashi S. etal. Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema. Thorax 2003; 58: 623-8.
36. Fujieda M., Yamazaki H., Saito T., Kiyotani K., Gyamfi M. A., Sakurai M. etal. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis 2004; 25: 2451-8.
37. Thorgeirsson T. E., Gudbjartsson D. F., Surakka I., Vink J. M., Amin N., Geller F. etal. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42: 448-53.
38. Loriot M. A., Rebuissou S., Oscarson M., Cenee S., Miyamoto M., Ariyoshi N. etal. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001; 11: 39-44.
39. Zhang X., Amemo K., Ameno S., Iwahashi K., Kinoshita H., Kubota T. etal. Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population. Nihon Arukoru Yakubutsu Igakkai Zasshi 2001; 36: 486-90.
40. Lerman C., Jepson C., Wileyto E. P., Patterson F., Schnoll R., Mroziewicz M. etal. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010; 87: 553-7.
41. Ho M. K., Mwenifumbo J. C., Al Koudsi N., Okuyemi K. S., Ahluwalia J. S., Benowitz N. L. etal. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009; 85: 635-43.
42. Patterson F., Schnoll R. A., Wileyto E. P., Pinto A., Epstein L. H., Shields P. G. etal. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008; 84: 320-5.
43. Lerman C., Tyndale R., Patterson F., Wileyto E. P., Shields P. G., Pinto A. etal. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79: 600-8.
44. Schnoll R. A., Patterson F., Wileyto E. P., Tyndale R. F., Benowitz N., Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009; 92: 6-11.
45. Malaiyandi V., Goodz S. D., Sellers E. M., Tyndale R. F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev 2006; 15: 1812-9.
46. Pitarque M., von Richter O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284: 455-60.
47. Xu C., Rao Y. S., Xu B., Hoffmann E., Jones J., Sellers E. M. etal. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 2002; 290: 318-24.
48. Chen Z., Lee L., Chen J., Collins R., Wu F., Guo Y. etal. Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). Int J Epidemiol 2005; 34: 1243-9.
49. Wang H., Qiu Q., Tan L. L., Liu T., Deng X. Q., Chen Y. M. etal. Prevalence and determinants of diabetes and impaired fasting glucose among urban community-dwelling adults in Guangzhou, China. Diabetes Metab 2009; 35: 378-84.
50. Benowitz N. L. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009; 49: 57-71.
51. Fukami T., Nakajima M., Sakai H., McLeod H. L., Yokoi T. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J 2006; 6: 401-12.
52. Ho M. K., Mwenifumbo J. C., Zhao B., Gillam E. M., Tyndale R. F. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 2008; 18: 67-75.
53. Ariyoshi N., Sawamura Y., Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun 2001; 281: 810-4.
54. Oscarson M., Gullsten H., Rautio A., Bernal M. L., Sinues B., Dahl M. L. etal. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998; 438: 201-5.
55. Hadidi H. F., Cholerton S., Monkman S. C., Armstrong M., Irshaid Y. M., Rawashdeh N. M. etal. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics 1994; 4: 159-61.
56. Ariyoshi N., Takahashi Y., Miyamoto M., Umetsu Y., Daigo S., Tateishi T. etal. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics 2000; 10: 687-93.
57. Kitagawa K., Kunugita N., Kitagawa M., Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 2001; 276: 17830-5.
58. Nunoya K., Yokoi T., Kimura K., Inoue K., Kodama T., Funayama M. etal. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3, 5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8: 239-49.
59. Al Koudsi N., Hoffmann E. B., Assadzadeh A., Tyndale R. F. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol 2010; 66: 239-51.
60. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519.
61. Doll R. Smoking and disease: prospects for control. R Soc Health J 1977; 97: 167-76.
62. Doll S. R. Smoking and lung cancer. Am J Respir Crit Care Med 2000; 162: 4-6.
63. Kohrman M. New steps for tobacco control in and outside of China. Asia Pac J Public Health 2010; 22: 189S-96S.
64. Hyland A., Higbee C., Borland R., Travers M., Hastings G., Fong G. T. etal. Attitudes and beliefs about secondhand smoke and smoke-free policies in four countries: findings from the International Tobacco Control Four Country Survey. Nicotine Tob Res 2009; 11: 642-9.
65. Sussman S., Pokhrel P., Black D., Kohrman M., Hamann S., Vateesatokit P. etal. Tobacco control in developing countries: Tanzania, Nepal, China, and Thailand as examples. Nicotine Tob Res 2007; 9: S447-57.
66. Kohrman M. Smoking among doctors: governmentality, embodiment, and the diversion of blame in contemporary China. Med Anthropol 2008; 27: 9-42.
67. Tyndale R. F., Sellers E. M. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 2001; 29: 548-52.
68. Runkel M., Bourian M., Tegtmeier M., Legrum W. The character of inhibition of the metabolism of 1, 2-benzopyrone (coumarin) by grapefruit juice in human. Eur J Clin Pharmacol 1997; 53: 265-9.
69. Madan A., Graham R. A., Carroll K. M., Mudra D. R., Burton L. A., Krueger L. A. etal. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31: 421-31.